Abstract

BackgroundMyostatin is a negative regulator of skeletal muscle growth. Truncating mutations in the myostatin gene have been reported to result in gross muscle hypertrophy. Duchenne muscular dystrophy (DMD), the most common lethal muscle wasting disease, is a result of an absence of muscle dystrophin. Although this disorder causes a rather uniform pattern of muscle wasting, afflicted patients display phenotypic variability. We hypothesized that genetic variation in myostatin is a modifier of the DMD phenotype.MethodsWe analyzed 102 Japanese DMD patients for mutations in the myostatin gene.ResultsTwo polymorphisms that are commonly observed in Western countries, p.55A>T and p.153K>R, were not observed in these Japanese patients. An uncommon polymorphism of p.164E>K was uncovered in four cases; each patient was found to be heterozygous for this polymorphism, which had the highest frequency of the polymorphism observed in the Japanese patients. Remarkably, two patients were found to be heterozygous for one of two novel missense mutations (p.95D>H and p.156L>I). One DMD patient carrying a novel missense mutation of p.95D>H was not phenotypically different from the non-carriers. The other DMD patient was found to carry both a novel mutation (p.156L>I) and a known polymorphism (p.164E>K) in one allele, although his phenotype was not significantly modified. Any nucleotide change creating a target site for micro RNAs was not disclosed in the 3' untranslated region.ConclusionOur results indicate that heterozygous missense mutations including two novel mutations did not produce an apparent increase in muscle strength in Japanese DMD cases, even in a patient carrying two missense mutations.

Highlights

  • Myostatin is a negative regulator of skeletal muscle growth

  • Disruption of endogenous myostatin by gene or RNA targetings was shown to result in anatomic, biochemical, and physiologic improvements in the dystrophic phenotype of mdx mice, a mouse model of Duchenne muscular dystrophy (DMD) with a nonsense mutation in the dystrophin gene [21,22], including prominent enlarged fiber diameters and greatly reduced fatty fibrosis. These results suggest that blocking endogenous myostatin is a potential strategy for treatment of DMD [23]

  • All three coding regions and a part of the 3' untranslated region of the myostatin gene were successfully PCR amplified from genomic DNA; 102 DNA samples were subjected to direct sequencing

Read more

Summary

Introduction

Truncating mutations in the myostatin gene have been reported to result in gross muscle hypertrophy. Duchenne muscular dystrophy (DMD), the most common lethal muscle wasting disease, is a result of an absence of muscle dystrophin. This disorder causes a rather uniform pattern of muscle wasting, afflicted patients display phenotypic variability. Duchenne muscular dystrophy (DMD), the most common inherited myopathy affecting approximately one in 3,500 males, is characterized by muscle dystrophin deficiency. DMD is known to progress with a rather uniform pattern of muscle weakness, the existence of a modifying gene has been suggested due to the identification of unusually mild DMD phenotypes [2,3,4]. The same dystrophin mutation has been reported to result in different phenotypes [11,12]

Methods
Results
Discussion
Conclusion
Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.